Sunday, June 22, 2025 6/22/2025

MOLECULAR MAMMOGRAPHY OF HER-2 CANCERS USING GOLD NANOPARTICLES

Award Number: R44CA124190
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/26/2006
PERIOD OF PERFORMANCE END DATE: 07/31/2012

Group Awards By:

View Award Description

MOLECULAR MAMMOGRAPHY OF HER-2 CANCERS USING GOLD NANOPARTICLES - DESCRIPTION (provided by applicant): Cancer imaging is important for tumor detection, determination of prognosis and treatments, image guided surgery and irradiation, as well as for monitoring responses. Molecular imaging of specific targets could identify tumor types and enable selection of appropriate drugs. Although x-ray imaging is widely used and more rapid with higher resolution compared to PET, SPECT, and MRI, there are currently no targeted x-ray contrast agents. In this proposal we will develop molecular targeted agents for mammography by a nanotechnology approach using gold nanoparticles for imaging cancers. The Her 2 protein on breast cancer cells will be targeted by use of antibodies attached to biocompatible gold nanoparticles using a mouse model. This would then be useful for non-invasive in vivo detection of this mutation which occurs in about 30% of human breast cancers that could then be beneficially treated with the monoclonal antibody Herceptin(r). Molecular mammography imaging would improve on the limited sampling afforded by painful biopsies and provide more thorough detection of even small tumors and metastases missed by biopsies and other methods. It would enable earlier detection of breast cancer. Better tumor definition would also improve precise radiotherapy, surgery, and follow-up monitoring. If successful, this technology could be applied to other tumors for early detection and biochemical typing for more effective individualized treatments. To Public Health: A novel method using nanotechnology will be developed for improved non-invasive imaging and detection of breast cancer types by mammography. This should not only enable better early detection of smaller tumors and metastases without painful biopsies, but identify tumor types so that specific drugs for the type can be administered. Such a need exists to detect Her2 breast cancers, which account for about 30% of breast cancers, where the specific drug Herceptin(r) is available and improves survival.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2011 ( Subtotal = $0 )
2011	2009	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	3	9/15/2011	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2009 ( Subtotal = $778,586 )
2009	2009	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Detection and Diagnosis Research	001	3	7/30/2009	NON-COMPETING CONTINUATION	$483,193
2009	2009	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Trans-NIH Recovery Act Research Support	002	3	9/29/2009	SUPPLEMENT FOR EXPANSION	$295,393
2009	2008	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	3/16/2009	EXTENSION WITH OR WITHOUT FUNDS	$0
														Subtotal = $778,586

Issue Date FY: 2008 ( Subtotal = $474,069 )
2008	2008	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	7/28/2008	EXTENSION WITH OR WITHOUT FUNDS	$474,069
														Subtotal = $474,069

Issue Date FY: 2006 ( Subtotal = $179,787 )
2006	2006	NANOPROBES, INC	95 HORSEBLOCK RD	YAPHANK	NY	11980	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	1	9/26/2006	NEW	$179,787
														Subtotal = $179,787

Grand Total All Awards = $1,432,442

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MOLECULAR MAMMOGRAPHY OF HER-2 CANCERS USING GOLD NANOPARTICLES

Award Number: R44CA124190

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/26/2006

PERIOD OF PERFORMANCE END DATE: 07/31/2012

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer